Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Bullboard Posts
Comment by longterm56on Oct 11, 2019 8:23pm
171 Views
Post# 30224365

RE:RE:RE:RE:RE:RE:RE:$150 million Shelf Offering just registered

RE:RE:RE:RE:RE:RE:RE:$150 million Shelf Offering just registeredI'm curious, SPCEO, what would be YOUR good/better/best share price for a new offering ... when it haappens?

  -LT


SPCEO1 wrote: Reiterating what I said already, a shelf offering is an offering that sits on the "shelf" until they actually need the money. They are not raising money right now.

scarlet1967 wrote:
palinc2000 wrote:

Remember a few weeks ago when Luc said TH had enough cash to fund the small Phase 3 trial!!!
 

 

scarlet1967 wrote: They don't need that much even if they get the approval for Nash hiv application, they haven't even start the communication with authorities.
Why do they need $150 millions?
I wish they could share more with investors, we have no clue what's going on.

 

 


I remember clearly when they did the webcast for hiv Nash one of the questions was the structure and cost of the phase 3 and the answer was 15 to 20 millions for two stages total 40 millions and they also said they can fund it with money in the bank and future earnings.
So again before even talking to authorities and get the application approved why try to raise money? Mysterious as usual with this company.




Bullboard Posts